Skip to content

Distalmotion raises $ 150M

Share this article

The fundraise, led by Revival Healthcare Capital, will be used to get a Food and Drug Administration (FDA) approval for Dexter, Distalmotion’s robotic surgery device.


Dexter, Distalmotion’s robotic platform, is already in day-to-day clinical use in Europe, successfully treating patients across a multitude of complex and high-volume procedures in general surgery, gynecology, urology. This funding will enable the way for US Food and Drug Administration (FDA) approval and to continue acceleration of clinical experience in Europe. “
“Dexter allows for ‘on-demand robotics’ and gives surgeons access to the benefits of both robotic and laparoscopic surgery, enabling best-in-class minimally invasive care for the patients,” explained Distalmotion CEO Michael Friedrich. “Surgeons can choose to operate entire procedures robotically, or they can leverage the ability to easily switch between the robotic and laparoscopic modalities to perform specialized tasks such as stapling with their preferred and trusted instruments. Surgeons are therefore empowered with choice and control.”
Dexter makes robotic surgery more accessible, enabling a wider adoption of robotic surgery. Dexter is easily integrated into clinical practice – it requires no additional infrastructure, it fits into every clinical setting, and it is mobile allowing for easy sharing across departments. This empowers institutions to scale robotics programs across surgical disciplines to offer more patients an enhanced standard of care in both hospital and surgery center settings.“
Dexter delivers what surgeons need most for when it matters most. It provides advanced dexterity for complex surgical steps such as suturing, dissection and working in confined spaces” said Prof. Dieter Hahnloser, head of colorectal surgery at Lausanne University Hospital who performed the first general surgery procedure with Dexter in 2021.
“Dexter’s open platform allows surgeons to choose the best in-class tools and technology for each step of the procedure. It is compatible with all 3D laparoscopes which allows surgeons to leverage current and future imaging innovations.”“This latest financing sets the stage for Distalmotion to accelerate our mission of expanding the adoption of Dexter to hospitals worldwide,” said Rick Anderson, Chairman of Revival and Chairman of Distalmotion. “We are very proud of our global leadership team’s accomplishment to bring Distalmotion’s technology to the market and to set the stage for the company’s entry into the US market”.
About Distalmotion
Distalmotion is a medical device company founded and based at the Biopôle in Lausanne. Its mission is to establish a new standard of care, where all patients in general surgery, gynecology and urology have access to best-in-class minimally invasive care. To do so, we have developed a surgical robot called Dexter®. Designed, developed and manufactured in Switzerland, Dexter integrates the benefits of laparoscopy and robotics. Dexter’s novel, on-demand approach to robotic surgery offers laparoscopic surgeons direct access to the patient and the robot at all times. Dexter is the world’s first and only on-demand robotic surgery system.